0000000000201782

AUTHOR

D Alvaro

showing 2 related works from this author

Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid

2022

Background & Aims Obeticholic acid (OCA) has recently been restricted in patients with primary biliary cholangitis (PBC) with "advanced cirrhosis" because of its narrow therapeutic index. We aimed to better define the predicting factors of hepatic serious adverse events (SAEs) and non-response in cirrhotic patients undergoing OCA therapy. Methods Safety and efficacy of treatment were evaluated in a cohort of consecutive PBC cirrhotic patients started with OCA. OCA response was evaluated according to the Poise criteria. Risk factors for hepatic SAEs and non-response were reported as risk ratios (RR) with 95% confidence intervals (CIs). Results One hundred PBC cirrhotics were included, 97…

Liver CirrhosisMaleliver decompensationsafetyHepatologyLiver Cirrhosis Biliarydecision curve analysis; efficacy; liver decompensation; safety; total bilirubin; Albumins; Ascites; Bilirubin; Chenodeoxycholic Acid; Humans; Liver Cirrhosis; Male; Liver Cirrhosis BiliaryBiliaryefficacyAscitesBilirubinChenodeoxycholic Acidtotal bilirubindecision curve analysiSettore MED/12AlbuminsHumansdecision curve analysis
researchProduct

HUMAN LEUKOCYTE ANTIGEN POLYMORPHISMS IN ITALIAN PRIMARY BILIARY CIRRHOSIS: A MULTICENTER STUDY OF 664 PATIENTS AND 1992 HEALTHY CONTROLS

2008

Genetic factors are critical in determining susceptibility to primary biliary cirrhosis (PBC), but there has not been a clear association with human leukocyte antigen (HLA) genes. We performed a multicenter case-control study and analyzed HLA class II DRB1 associations using a large cohort of 664 well-defined cases of PBC and 1992 controls of Italian ancestry. Importantly, healthy controls were rigorously matched not only by age and sex, but also for the geographical origin of the proband four grandparents (Northern, Central, and Southern Italy). After correction for multiple testing, DRB1*08 [odds ratio (OR), 3.3; 95% confidence interval (CI), 2.4-4.5] and DRB1*02 (OR 0.9; 95% CI 0.8-1.2) …

ProbandLiver CirrhosisMaleCohort StudiesPrimary biliary cirrhosisGene FrequencyModelsGenotype80 and overMedicineskin and connective tissue diseasesAged 80 and overSettore MED/12 - GastroenterologiaLiver Cirrhosis BiliaryMedicine (all)BiliaryMiddle AgedItalyHLA-DRB1 ChainFemaleCase-Control StudieHumanmusculoskeletal diseasesAdultGenotypeHuman leukocyte antigenArticleGeneticGenetic modelHumansGenetic Predisposition to DiseasePolymorphismAllele frequencyAgedPolymorphism GeneticHepatologyModels Geneticbusiness.industryCase-control studyOdds ratioHLA-DR Antigensmedicine.diseaseHLA-DR AntigenAdult; Aged; Aged 80 and over; Case-Control Studies; Cohort Studies; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; HLA-DR Antigens; Humans; Italy; Liver Cirrhosis Biliary; Male; Middle Aged; Models Genetic; Polymorphism GeneticCase-Control StudiesImmunologyprimary bilairy cirrhosis geneticsCohort StudiebusinessHLA-DRB1 Chains
researchProduct